Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2010
02/25/2010US20100047364 Nutrient System for Individualized Responsive Dosing Regimens
02/25/2010US20100047363 Nutritional supplement for patients with chronic kidney disease
02/25/2010US20100047360 Use Of Polyamines In The Treatment Of Psoriasis
02/25/2010US20100047359 Stable powder formulation containing a novel anticholinergic agent
02/25/2010US20100047357 Compositions for topical application comprising a peroxide and retinoid
02/25/2010US20100047356 Charge-assembled capsules for phototherapy
02/25/2010US20100047354 Combretum laurifolium mart. extract and methods of extracting and using such extract
02/25/2010US20100047349 Stabilized solid preparation
02/25/2010US20100047348 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
02/25/2010US20100047347 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
02/25/2010US20100047346 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
02/25/2010US20100047345 Hydrophobic abuse deterrent delivery system for hydromorphone
02/25/2010US20100047343 Multiparticulate formulation having tramadol in immediate and controlled release form
02/25/2010US20100047342 Method and Composition for Administering an NMDA Receptor Antagonist to a Subject
02/25/2010US20100047341 Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory
02/25/2010US20100047340 Hot-melt extrusion of modified release multi-particulates
02/25/2010US20100047339 Compositions for the treatment of chronic degenerative inflammatory conditions
02/25/2010US20100047338 Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
02/25/2010US20100047337 Pharmaceutical spheroids
02/25/2010US20100047336 Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
02/25/2010US20100047332 Treatments for burns using thyroid hormone compound in a human
02/25/2010US20100047330 Treatment for dark adaptation
02/25/2010US20100047328 Adhesive preparation
02/25/2010US20100047327 Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
02/25/2010US20100047326 Multiple-Compartment Applicator
02/25/2010US20100047325 Analgesic anti-inflammatory patches for topical use
02/25/2010US20100047323 Chitosan solution and medical preparation with chitosan coating formed from the solution
02/25/2010US20100047322 Combination antihypertensive wafer
02/25/2010US20100047315 protective coating, spray coating; drug delivery; cardiovascular disorders
02/25/2010US20100047314 Folinic acid derivatives for promoting bone growth
02/25/2010US20100047313 Medical devices having a coating for electromagnetically-controlled release of therapeutic agents
02/25/2010US20100047312 Use of bioactive and radiopaque material for stent coating
02/25/2010US20100047307 Injectable drug carrier comprising layered double hydroxide
02/25/2010US20100047306 Pharmaceutical compositions comprising bisphosponates
02/25/2010US20100047299 Use of gdf-5 for the improvement or maintenance of dermal appearance
02/25/2010US20100047298 Process for treating the skin by applying silicone compounds
02/25/2010US20100047292 Methods of processing microparticles and compositions produced thereby
02/25/2010US20100047280 Flavivirus ns1 subunit vaccine
02/25/2010US20100047276 Recombinant Vectors Based On the Modified Vaccinia Ankara Virus (MVA) as Preventive and Therapeutic Vaccines Against Aids
02/25/2010US20100047265 Active antiangiogenic therapy
02/25/2010US20100047263 Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
02/25/2010US20100047260 Methods and Compositions Relating To a Vaccine Against Prostate Cancer
02/25/2010US20100047258 Drug Carriers, Their Synthesis, and Methods of Use Thereof
02/25/2010US20100047256 Methods
02/25/2010US20100047255 Novel activation and transfer cascade for ubiquitin
02/25/2010US20100047248 Methods of processing compositions containing microparticles
02/25/2010US20100047246 Methods and Compositions for Treating Vascular Disease
02/25/2010US20100047235 Novel regimens for treating diseases and disorders
02/25/2010US20100047233 Treatment of post-menopausal and post-hysterectomy mediated cognitive disorders
02/25/2010US20100047223 Pharmanutrient Composition(s) and System(s) for Individualized, Responsive Dosing Regimens
02/25/2010US20100047221 Compositions comprising pyruvate alkyl esters and uses thereof
02/25/2010US20100047210 Systems and Methods for Positioning of Needles and Other Devices Within Body Tissue
02/25/2010US20100047198 Textile Scenting
02/25/2010US20100047197 Cosmetic formulation contaning glucosyl glycerides and urea
02/25/2010US20100047196 Novel microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics
02/25/2010US20100047195 Lip balm and method of treating lip conditions
02/25/2010US20100047192 Novel tyrosinase-specific anti-gene oligonucleotides as depigmenting agents
02/25/2010US20100047188 Modulation of toll-like receptor 8 expression by antisense oligonucleotides
02/25/2010US20100047187 Methods of treating parkinson's disease using halogenated volatile compounds
02/25/2010US20100047184 Pharmaceutical compositions containing an effervescent acid-base couple
02/25/2010US20100047181 Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller
02/25/2010US20100047179 Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production
02/25/2010US20100047178 Perylenequinone derivatives and uses thereof
02/25/2010US20100047177 treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent that increases AMP activated kinase (AMPK), LKB1 and CaMKK beta acitvity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration
02/25/2010US20100047162 Methods of processing multi-phasic dispersons
02/25/2010DE102008039254A1 Medicament, useful e.g. for treating infectious- and purulent inflammatory diseases of e.g. eyes, comprises benzyl-dimethyl-(3-(myristoylamino)-propyl)-ammonium chloride, dimethyl-(3-(myristoylamino)-propyl)-amine oxide and solvent
02/25/2010DE102008039231A1 Verwendung von Glucosylglycerol Use of Glucosylglycerol
02/25/2010DE102008038222A1 Indazol-5-carbonsäurehydrazid-derivate Indazole-5-carboxylic acid derivatives
02/25/2010DE102008038221A1 7-Azaindolderivate 7-azaindole derivatives
02/25/2010DE102008038220A1 Oxadiazolderivate Oxadiazole
02/25/2010DE102006053593B4 Verfahren zur Herstellung von Letrozol Process for the preparation of letrozole
02/25/2010CA2806444A1 Prodrugs of methyl hydrogen fumarate
02/25/2010CA2771226A1 New bradykinin b1 antagonists
02/25/2010CA2735130A1 Compounds and methods for treating respiratory diseases
02/25/2010CA2735058A1 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
02/25/2010CA2735050A1 Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
02/25/2010CA2735048A1 6-substituted 2-(benzimidazolyl)purine and purinone derivatives and 6-substituted 2-(imidazolo[4,5- c]pyridinyl)purine and purinone derivatives for immunosuppression
02/25/2010CA2734972A1 An extended release pharmaceutical composition of entacapone or salts thereof
02/25/2010CA2734917A1 Heterogeneous polymeric micelles for intracellular delivery
02/25/2010CA2734900A1 Polymorphic form of granisetron hydrochloride and methods of making the same
02/25/2010CA2734896A1 Therapeutic substituted pyrroles
02/25/2010CA2734892A1 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
02/25/2010CA2734877A1 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
02/25/2010CA2734870A1 Therapeutic agent for anca-related vasculitis
02/25/2010CA2734866A1 Complement inhibitors for treatment of injury from intracerebral hemorrhage
02/25/2010CA2734863A1 Regulation of integrin surface expression
02/25/2010CA2734859A1 Methods for treating cns disorders
02/25/2010CA2734831A1 Triazolopyridine compounds as pim kinase inhibitors
02/25/2010CA2734828A1 Chemoprevention of head and neck squamous cell carcinomas
02/25/2010CA2734809A1 Dabigatran in tumour therapy
02/25/2010CA2734804A1 Use of dabigatranetexilate for treating patients with pulmonary hypertension
02/25/2010CA2734802A1 Pyrrolopyrimidine compounds as cdk inhibitors
02/25/2010CA2734797A1 Treatment of anxiety disorders
02/25/2010CA2734794A1 Dabigatran for percutaneous interventional cardiac catheterisation
02/25/2010CA2734787A1 Substituted 5-aminopyrazoles and use thereof
02/25/2010CA2734780A1 Short acting benzothiazepine calcium channel blockers and uses thereof
02/25/2010CA2734769A1 Use of d-ribose for fatigued subjects
02/25/2010CA2734763A1 Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
02/25/2010CA2734755A1 Treatment and/or prevention of peanut induced anaphylaxis
02/25/2010CA2734720A1 Hydroxybutyrate ester and medical use thereof
1 ... 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 ... 7860